Q3 FY2025 · ended Sep 30, 2025 · Revenue $146,000, +15.9% YoY · Filed Nov 14, 2025
Valion Bio, Inc. (VBIO) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$5.3 million. As of Jun 30, 2026 it held $2.1 million in cash and investments and $10.0 million in total debt.
Revenue
$146,000
+15.9% vs year-ago quarter
Net income
$-7.10M
-267.8% vs year-ago quarter
Operating cash flow
$-5.28M
-189.1% vs year-ago quarter
Free cash flow
$-5.34M
-191.7% vs year-ago quarter
EPS
$-2.19
+13.1% vs prior quarter
Dividend per share
None
Shares outstanding
22.19M
+1948.9% vs year-ago quarter
Net cash
$-7.91M
Q2 FY2026
Operating margin
-1290.7%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VBIO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Antonio, TX
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1787740
- Former names
- Tivic Health Systems, Inc. (until Apr 23, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $146,000 | $86,000 |
| Operating income | -$6.4M | -$5.6M | -$2.0M | -$2.5M | -$1.7M |
| Net income | -$7.1M | -$6.2M | -$2.8M | -$2.6M | -$1.9M |
| Diluted EPS | — | — | — | — | -$2.19 |
| Operating cash flow | -$5.3M | -$5.0M | -$2.3M | -$2.0M | -$1.8M |
| Free cash flow | -$5.3M | -$5.0M | -$2.3M | -$2.0M | -$1.8M |
| Total assets | $32.5M | $38.2M | $31.6M | $6.2M | $4.5M |
| Total liabilities | $20.6M | $19.7M | $7.4M | $638,000 | $821,000 |
| Stockholders' equity | $4.2M | $11.1M | $16.8M | $3.4M | $3.7M |
| Cash and investments | $2.1M | $7.2M | $12.6M | $3.5M | $1.2M |
| Total debt | $10.0M | $10.1M | — | — | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Other events
|
Nov 2, 2026 | Oct 27, 2026 |
| 8-K |
Current report
Other events
|
Oct 29, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Oct 27, 2026 | Oct 26, 2026 |
| 8-K |
Current report
Other events
|
Oct 26, 2026 | Oct 26, 2026 |
| 8-K |
Current report
Other events
|
Oct 22, 2026 | Oct 21, 2026 |
| 8-K |
Current report
Other events
|
Oct 15, 2026 | Oct 15, 2026 |
All 402 Valion Bio, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.